Jay Luly

The hepatitis C industry has been on fire since Merck (NYSE: MRK) paid a 230 percent premium for pharmaceutical company Idenix (NASDAQ: IDIX). Benzinga spoke to Enanta (NASDAQ: ENTA) CEO Jay Luly about possibilities for his firm, which has one of the most expansive hepatitis C pipelines of all...

Merck (NYSE: MRK) paid a 230 percent premium for Hepatitis C-focused Idenix Pharmaceuticals (NASDAQ: IDIX). News of the massive acquisition, earlier this month, sent shares of other Hep C companies, Enanta (NASDAQ: ENTA) and Achillion (NASDAQ: ACHN) higher. In an exclusive interview with...